TSE:HBP Helix BioPharma (HBP) Stock Price, News & Analysis C$1.10 -0.07 (-5.98%) As of 09/23/2026 03:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsNews and Trends About Helix BioPharma Stock (TSE:HBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Helix BioPharma alerts:Sign Up Key Stats Today's RangeC$1.10▼C$1.1850-Day RangeC$1.10▼C$2.0552-Week RangeC$1.10▼C$5.40Volume54,139 shsAverage Volume2,779 shsMarket CapitalizationC$84.02 millionP/E RatioN/ADividend Yield1.50%Price TargetN/AConsensus RatingN/A Company Overview Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA¿, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA¿, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers. Read More Receive HBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBP Stock News HeadlinesKurs Helix BioPharma Corp.September 20, 2026 | de.marketscreener.comDHelix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical DevelopmentAugust 17, 2026 | finance.yahoo.comNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.September 24 at 1:00 AM | Behind the Markets (Ad)Helix BioPharma Taps Veteran Oncologist Markus Loeffler as CMO for Next Clinical PhaseAugust 17, 2026 | tipranks.comHelix BioPharma Reshapes Board to Align with Oncology Growth StrategyAugust 14, 2026 | tipranks.comHelix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical DevelopmentJune 30, 2026 | finance.yahoo.comHelix BioPharma Showcases CEACAM6-Targeted ADC Advances at World ADC LondonFebruary 24, 2026 | tipranks.comHelix BioPharma Extends LEUMUNA Option with metaShape in Metabolic Disease PushFebruary 5, 2026 | tipranks.comSee More Headlines HBP Stock Analysis - Frequently Asked Questions How have HBP shares performed this year? Helix BioPharma's stock was trading at C$2.37 at the beginning of the year. Since then, HBP stock has decreased by 53.6% and is now trading at C$1.10. How were Helix BioPharma's earnings last quarter? Helix BioPharma Corp. (TSE:HBP) posted its quarterly earnings data on Thursday, October, 24th. The biopharmaceutical company reported ($0.11) EPS for the quarter. How do I buy shares of Helix BioPharma? Shares of HBP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Helix BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Helix BioPharma investors own include Enterprise Products Partners (EPD), GrowGeneration (GRWG), Green Thumb Industries (GTBIF), Amplify Seymour Cannabis ETF (CNBS), Cenovus Energy (CVE), Enbridge (ENB) and Micron Technology (MU). Company Calendar Last Earnings10/24/2024Today9/24/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolTSE:HBP CIKN/A Webwww.helixbiopharma.com Phone+1-416-9253232FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$50.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.54% Return on Assets-279.98% Debt Debt-to-Equity Ratio2.44 Current Ratio0.45 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.10 per share Price / Cash Flow11.32 Book ValueC$0.19 per share Price / Book5.72Miscellaneous Outstanding Shares76,378,000Free FloatN/AMarket CapC$84.02 million OptionableNot Optionable Beta0.72 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (TSE:HBP) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Helix BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Helix BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
